Please login to the form below
neurodegenerative disorder
This page shows the latest neurodegenerative disorder news and features for those working in and with pharma, biotech and healthcare.
FDA grants Prothena fast-track designation for next-generation Alzheimer’s disease therapy
Approximately 50 million people worldwide are estimated to be living with Alzheimer’s disease or other dementias, with Alzheimer’s disease being the most common neurodegenerative disorder.
Latest news
-
Study provides new insights into Alzheimer's disease
A team of international researchers has identified 75 regions of the genome that are associated with Alzheimer's disease in the largest study of genetics in the neurodegenerative disorder to date. ... Alzheimer’s disease is a chronic neurodegenerative
-
AbbVie acquires Syndesi Therapeutics in $1bn deal
The deal will allow AbbVie to access Syndesi’s research into the potential treatment of cognitive impairment and other symptoms associated with neurodegenerative and neuropsychiatric disorders, including major depressive disorder and ... With AbbVie's
-
UniQure cleared to start Huntington gene therapy trial
The US regulator has approved UniQure’s investigational new drug (IND) application for a phase 1/2 trial of AMT-130 in rare genetic neurodegenerative disorder Huntington’s disease, and the
-
UniQure’s starts pivotal haemophilia B gene therapy trial
in development for Huntington’s disease, a neurodegenerative disorder with no approved therapies.
-
Takeda ties-up with Denali Therapeutics for neuroscience boost
Takeda Pharmaceuticals and Denali Therapeutics have entered a partnership to develop and commercialise therapies for multiple neurodegenerative diseases. ... The collaboration will see the companies produce up to three specified therapeutic product
More from news
Approximately 3 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
Key considerations for disease- modifying Parkinson’s disease trials
Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s.The anti-Parkinson medications available primarily promote dopamine levels in the brain to compensate for the loss of ... The design of such neuroprotective
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Improving healthcare for rare disease patients
In February this year, it was announced that the world’s most expensive drug: Libmeldy, a treatment for the debilitating rare neurodegenerative disorder metachromatic leukodystrophy (MLD), would be available to patients
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Consultant Dermatologist (Freelance)
-
£110-180ph
-
Head of Health Psychology, London
-
Highly competitive salary
-
Senior Health Psychologist, London
-
Highly competitive salary
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientists discover new approach to treat brain tumours
- Recognising HIV Vaccine Awareness Day
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- UICC launches global ATOM Coalition to increase access to essential cancer medicines
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- Live Webinar: The Future of MedTech: Streamlined Clinical Data Collection & Management
- Medscape: Connect to the conversation
- A Medscape 4-part video interview series
- Why big pharma needs to be braver
- MadMicrobe Studios Inc Announces New European Venture
- EMA accepts Valneva’s marketing authorisation application for COVID-19 vaccine
- Roche shares new positive Ocrevus data for MS patients
- First trial of a vaccine against Alzheimer’s launches
- Bristol Myers Squibb releases positive trial results for plaque psoriasis treatment
- MHRA approves Infex Therapeutics’s study for treatment for non-cystic fibrosis patients
- Creating an engaging experience for patients
- Mapping patient pathways – with a focus on patient-centricity
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- Why big pharma needs to be braver
- The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
- Food Allergy – Is avoidance the only option?
- Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
